arrow
K

Kevin Winthrop

Oregon Health and Science University
H指数:102
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial intelligence responses to bronchiectasis patients’ questions: the AIR-BE study

人工智能对支气管扩张患者问题的回应:AIR-BE研究

2026-09-170
PRE
Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease

难治性非结核分枝杆菌肺部疾病的管理共识

2026-01-011
PRE
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis

Chalmers, J.D.; Haworth, C.S.; Flume, P.; Long, M.B.; Burgel, P.R.; Dimakou, K.; Blasi, F.; Herrero-Cortina, B.; Dhar, R.; Chotirmall, S.H.; 等. 欧洲呼吸学会成人支气管扩张管理临床实践指南. Eur. Respir. J. 2025; 2501126, online ahead of print. [Google Scholar] [CrossRef]

2025-12-0122
PRE
Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

中华银屑病基金会医学委员会与国际银屑病委员会联合立场声明:关于在应用IL-17或IL-23抑制剂治疗银屑病患者前及治疗期间常规检测潜伏性结核感染的说明

2025-11-170
OAAI
Age-related severity of nontuberculous mycobacterial lung disease is mediated by aberrant macrophage responses and lung microbial dysbiosis

年龄相关的非结核分枝杆菌肺部疾病严重程度由异常的巨噬细胞反应和肺部微生物失调介导。

2025-10-100
OAAI
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease

乌帕替尼的安全性概况:在类风湿关节炎、银屑病关节炎、轴向脊柱关节炎、特应性皮炎和炎症性肠病中超过27,000患者年的描述性分析

2025-08-280
OAAI
An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years

关于filgotinib在中等至重度活动性类风湿关节炎患者中的综合安全性分析的中位4.3年更新。

2025-04-280
PRE
RCT Abstract - Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
2024-10-300
PRE